Cargando…
Massive atelectasis by mucoid impaction in an asthma patient during treatment with anti‐interleukin‐5 receptor antibody
Benralizumab is an interleukin‐5 (IL‐5) receptor α‐directed cytolytic monoclonal antibody that reduces rapid and nearly complete depletion of eosinophils by enhancing antibody‐dependent cell‐mediated cytotoxicity. The depletion of eosinophilic inflammation is expected to reduce mucus hypersecretion...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Ltd
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300730/ https://www.ncbi.nlm.nih.gov/pubmed/32566229 http://dx.doi.org/10.1002/rcr2.599 |